课题基金 / 基金详情

OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2

OVARIAN CARCINOMA TIL TREATMENT AFTER IFN GAMMA/IL2
IFN GAMMA/IL2 治疗后的卵巢癌
批准号:
2107694
负责人:
RALPH Stuart FREEDMAN
金额:
$18.2万
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
已结题
起止时间:
1994-08-01 至 1998-05-31

项目摘要

项目成果

RALPH Stuart FREEDMAN的其他基金

相似基金

相关文献

中文摘要
翻译
本交互式R 01提案的长期目标是开发 上皮性卵巢癌的新的有效治疗方法 (EOC)基于肿瘤浸润淋巴细胞的体内活化 (TIL)对自体肿瘤有特异性。 尽管最近取得了进展, 卵巢癌的化疗,这些患者的生存留下了很大的空间, 需要的话 在这项拨款申请中要测试的假设是, 卵巢TIL衍生的T细胞系可以从腹膜渗出物中产生 腹膜内(IP)预充后EOC患者的PEC 干扰素-λ(rLFN-lambda),然后是低剂量的IL-2。 在 特别是,我们将解决的问题,是否IP启动与这些 细胞因子与(a)肿瘤细胞比例增加相关 其在体内表达MHC I类和/或II类表面抗原;(B) 回收大量的CD 3 + TCR α +淋巴细胞, 腹腔(P.c.)表达CD 8+或CD 4+表型;(c) - 利用PCR扩增来自PEC的CD 8+或CD 4 + T细胞系的能力, T细胞纯化程序和(d)获得的T细胞系 在用rIFN-λ IP引发后,在(i_(max))方面表现出特异性。 自体肿瘤细胞溶细胞活性和/或(ii)细胞因子产生。 所有这些假说都集中在阐明作用机制, 在体内,这些TIL的,只能解决与 一项临床试验,在该试验中,EOC患者采用以下策略进行治疗: 过继转移的TIL从体内后获得的(PEC)发育 用rIFN-λ和IL-2引发。 临床试验遵循基本的 我们在EOC IP过继免疫治疗试验中使用的设计 患者 用rIFN-lambda进行IP预处理是我们试验的一个新特征 设计 (e)我们还将在一个单独的方案中检验这一假设 卵巢TIL衍生的T细胞系在肿瘤部位聚集, IP注射。 我们的具体目标是:确定IP启动是否 在EOC患者中,rIFN-λ和低剂量rIL-2相关 (1)MHC I类或II类表面抗原表达增加 (2)卵巢TIL衍生的T细胞的产生 来自PEC的细胞系,其(a)表达CD 8 + TCR α +或 CD 4 + TCR α +表型,和(B)在CD 4 + T细胞中显示肿瘤特异性活性。 术语(i)自体肿瘤细胞毒性和/或(ii)细胞因子 生产 其他具体目标是(3)确定频率, 毒性事件和/或临床反应的强度, 治疗策略,包括用细胞因子和IP预充IP 用rIFN-λ处理,然后用细胞因子引发的T细胞系处理, 低剂量rIL-2;(4)测定纯化的卵巢T细胞的能力 线集中在肿瘤部位。
英文摘要
The long-term objectives of this interactive R01 proposal are to develop new and effective treatment approaches for epithelial ovarian cancer (EOC) based upon the activation in vivo of tumor infiltrating lymphocytes (TIL) specific for autologous tumor. Notwithstanding recent advances in the chemotherapy of EOC the survival of these patients leaves much to be desired. The hypotheses to be tested in this grant application are that ovarian TIL-derived T-cell lines can be developed from peritoneal exudate cells (PEC) of EOC patients after intraperitoneal (IP) priming with interferon-lambda (rLFN-lambda) followed by low doses of IL-2. In particular, we will address the issues whether IP priming with these cytokines is correlated with (a) increased proportions of tumor cells that express MHC Class I and/or Class II surface antigens in vivo; (b) recovery of large numbers of CD3+TCRalphabeta+ lymphocytes from the peritoneal cavity (P.c.) that express either CD8+ or CD4+ phenotypes; (c) an ability to expand either CD8+ or CD4+ T-cell lines from PEC utilizing a T cell purification procedure and (d) that the T-cell lines obtained after IP priming with rIFN-lambda exhibit specificity in terms of (i_ autologous tumor cell cytolytic activity and/or (ii) cytokine production. All these hypotheses are focused on elucidating the mechanisms of action, in vivo, of these TILs and can be addressed only in conjunction with a clinical trial in which patients with EOC are treated with a strategy of adoptively transferred TIL developed from (PEC) obtained after in vivo priming with rIFN-lambda and IL-2. The clinical trial follows a basic design that we have used in IP adoptive immunotherapy trials of EOC patients. IP priming with rIFN-lambda is a novel feature of our trial design. (e) We will also test the hypothesis in a separate protocol that: ovarian TIL-derived T-cell lines concentrate at tumor sites after IP injection. Our specific aims are to: Determine whether IP priming of EOC patients with rIFN-lambda followed by low dose rIL-2 correlates with (1) Increased expression of MHC Class I or Class II surface antigens on EOC cells in vivo, and (2) Production of ovarian TIL-derived T-cell lines from PEC that (a) express either the CD8+TCRalphabeta+ or CD4+TCRalphabeta+ phenotype, and (b) exhibit tumor specific activity in terms of (i) Autologous tumor cell cytotoxicity and/or (ii) cytokine production. Other specific aims are to (3) Determine the frequency and intensity of toxic events and/or clinical responses that result from a treatment strategy that includes IP priming with cytokines and IP treatment with rIFN-lambda followed by cytokine primed T-cell lines and low dose rIL-2, and (4) Determine the ability of purified ovarian T-cell lines to concentrate at tumor sites.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Autologous therapeutic tumor vaccine + IFN-gamma
Phase ii intraperitoneal rhIL 12
Phase ii intraperitoneal rhIL 12
B7.1 COSTIMULATION IN OVARIAN CANCER
海外基金